Today is April 26, 2024.
All times in Eastern Daylight Time.
-
JPMorgan Chase Publishes 2023 Annual Report, Including Chairman & CEO Letter to Shareholders
NEW YORK--(BUSINESS WIRE)--JPMorgan Chase & Co. (NYSE: JPM) (“JPMorgan Chase” or the “Firm”) has published its 2023 Annual Report, including letters to shareholders from its Chairman & CEO ... more »
-
Barings BDC, Inc. Announces Conference Call to Discuss First Quarter 2024 Results
CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings BDC, Inc. (NYSE: BBDC) (“Barings BDC” or the “Company”) announced today that it will report its financial results for the first quarter ended March 31, 202... more »
-
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 more »
-
Quincy Data Distributes the Lowest Latency Market Data Between New Jersey and Toronto-TMX
OAKLAND, Calif.--(BUSINESS WIRE)--Quincy Data has launched the fastest market data service between the largest U.S. and Canadian equities exchanges. Quincy’s ultra-low latency QED service now distr... more »
-
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary E... more »
-
Perion Network Announces Preliminary Q1 2024 Financial Results
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Perion Network Ltd. (NASDAQ & TASE: PERI), a technology leader in connecting advertisers to consumers across all major digital channels, announced ... more »
-
Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce it has been recognized ... more »
-
Zura Bio Announces Robert Lisicki as CEO and Director
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases,... more »
-
Exact Sciences Schedules First Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter... more »
-
Expro Report Highlights Progress Unlocking Energy Answers of Tomorrow
HOUSTON--(BUSINESS WIRE)--Expro (NYSE: XPRO), a leading provider of energy services, has published its latest sustainability report, highlighting the Company’s achievements in 2023 along with the p... more »
-
SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment
TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine... more »
-
UMC Reports Sales for March 2024
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), today reported unaudited net sales for the month of March 2024. Revenues for March 2024 Period ... more »
-
Pan American Silver reports additional high-grade drill results from the La Colorada Skarn project
VANCOUVER, British Columbia--(BUSINESS WIRE)--Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS) ("Pan American" or the "Company") releases results from the ongoing infill and geotechnical drill pr... more »
-
Accenture to Acquire CLIMB to Expand Technology Capabilities
NEW YORK & TOKYO--(BUSINESS WIRE)--Accenture has agreed to acquire CLIMB, a technology services provider specializing in system integration. more »
-
Alcon Publishes Agenda for 2024 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2024 Annual General Meeting more »
-
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
ATLANTA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members... more »
-
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational ... more »
-
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating t... more »
-
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia... more »
-
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT.... more »
-
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight ... more »
-
Wipro Appoints Srini Pallia as CEO & Managing Director
EAST BRUNSWICK, N.J. & BENGALURU, India--(BUSINESS WIRE)--Wipro Limited announced the appointment of Srini Pallia as the Chief Executive Officer and Managing Director of the Company, effective imme... more »
-
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approve... more »
-
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors more »
-
Avangrid Statement on Gas Subsidiaries’ Response to 4.8 Magnitude Earthquake
ORANGE, Conn.--(BUSINESS WIRE)--Today, Avangrid (NYSE: AGR), a leading sustainable energy company and member of the Iberdrola Group, issued the following statement on behalf of its subsidiaries New... more »
|
|